Aquestive Therapeutics (NASDAQ:AQST) Reaches New 52-Week High – What’s Next?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) shares reached a new 52-week high during trading on Friday . The stock traded as high as $6.43 and last traded at $5.90, with a volume of 4892000 shares changing hands. The stock had previously closed at $5.26.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Lifesci Capital raised shares of Aquestive Therapeutics to a “strong-buy” rating in a report on Wednesday, September 3rd. Zacks Research raised shares of Aquestive Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 13th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a report on Tuesday, June 17th. Finally, Oppenheimer increased their price objective on shares of Aquestive Therapeutics from $7.00 to $8.00 and gave the company an “outperform” rating in a report on Monday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Aquestive Therapeutics presently has an average rating of “Buy” and a consensus price target of $10.29.

Aquestive Therapeutics Price Performance

The firm has a market capitalization of $597.35 million, a PE ratio of -8.56 and a beta of 1.82. The stock’s 50-day moving average price is $4.37 and its 200 day moving average price is $3.49.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Monday, August 11th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The company had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. Equities research analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Aquestive Therapeutics news, COO Cassie Jung sold 62,180 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $5.00, for a total value of $310,900.00. Following the completion of the sale, the chief operating officer directly owned 283,346 shares in the company, valued at $1,416,730. This trade represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Peter E. Boyd sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $5.30, for a total transaction of $79,500.00. Following the completion of the sale, the insider owned 288,323 shares of the company’s stock, valued at approximately $1,528,111.90. This trade represents a 4.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 77,580 shares of company stock worth $392,800. Insiders own 8.35% of the company’s stock.

Institutional Investors Weigh In On Aquestive Therapeutics

Several institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in Aquestive Therapeutics by 16.2% in the second quarter. Geode Capital Management LLC now owns 1,977,001 shares of the company’s stock valued at $6,545,000 after acquiring an additional 276,295 shares in the last quarter. Pale Fire Capital SE grew its holdings in shares of Aquestive Therapeutics by 25.5% during the second quarter. Pale Fire Capital SE now owns 1,676,451 shares of the company’s stock valued at $5,549,000 after buying an additional 340,767 shares during the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of Aquestive Therapeutics by 7.6% during the first quarter. Janney Montgomery Scott LLC now owns 1,059,760 shares of the company’s stock valued at $3,073,000 after buying an additional 75,275 shares during the last quarter. Sio Capital Management LLC grew its holdings in shares of Aquestive Therapeutics by 141.9% during the second quarter. Sio Capital Management LLC now owns 947,489 shares of the company’s stock valued at $3,136,000 after buying an additional 555,860 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Aquestive Therapeutics by 905.2% during the fourth quarter. Bank of America Corp DE now owns 690,284 shares of the company’s stock valued at $2,457,000 after buying an additional 621,614 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.